Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

Key Insights Significant control over IO Biotech by private equity firms implies that the general public has more ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Ultragenyx and partner Mereo BioPharma’s brittle bone disease trial will continue. Investors had wanted data good enough to ...

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: MoonLake ...

Each of these biotech stocks has real potential to tackle other health-related issues, some of which have plagued us for centuries. 7 Retail Stocks That You Don't Want In Your Cart ...

Should Investors Be Watching these Top Biotech Stocks Right Now?As we approach the end of 2021, it seems that biotech stocks could continue to make viable plays in the stock market. This can be ...

The move higher in biotech stocks comes after a rough start in the first half of the year, when the biotech index lost 17.7%, more than it lost in the first six months of any year since 2016.